PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28500237-3	2017	Here, we demonstrate that ponatinib exhibits potent antiproliferative activity in RET fusion-positive LC-2/ad lung adenocarcinoma cells and inhibits phosphorylation of the RET fusion protein and signaling through ERK1/2 and AKT.	ponatinib	26-35	AKT serine/threonine kinase 1	Homo sapiens	224-227	
35603651-0	2022	(Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways).	ponatinib	1-10	AKT serine/threonine kinase 1	Homo sapiens	108-111	
35603651-11	2022	A number of kinase signaling pathways were inhibited by ponatinib, including the Src signaling pathway, MAPK pathway and PDK1/AKT/mTOR pathway.	ponatinib	56-65	AKT serine/threonine kinase 1	Homo sapiens	126-129	
35603651-12	2022	Conclusion Ponatinib can inhibit the proliferation, promote the apoptosis and cell cycle arrest of hepatocellular cancer cells and block MAPK and PDK1/AKT/mTOR signaling pathways, which might be a potential agent for liver cancer treatment.	ponatinib	11-20	AKT serine/threonine kinase 1	Homo sapiens	151-154	
32470534-8	2020	Additionally, we will review the recent discoveries reported by our and other laboratories that ponatinib primarily exerts its cardiotoxicity via an off-target effect on cardiomyocyte prosurvival signaling pathways, AKT and ERK.	ponatinib	96-105	AKT serine/threonine kinase 1	Homo sapiens	216-219	
30959969-0	2019	Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling.	ponatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	136-139	
22409268-6	2012	These observations correlated with a strong inhibition of FLT3-ITD and its downstream targets STAT5, AKT and ERK1/2 upon ponatinib incubation, as determined by Western blotting.	ponatinib	121-130	AKT serine/threonine kinase 1	Homo sapiens	101-104	
28427224-7	2017	Ponatinib reduced merlin-deficient HSC viability in a dose-dependent manner by decreasing phosphorylation of PDGFRalpha/beta, AKT, p70S6K, MEK1/2, ERK1/2 and STAT3.	ponatinib	0-9	AKT serine/threonine kinase 1	Homo sapiens	126-129	
27783942-4	2016	Inhibitor combinations targeting both receptors and the dual inhibitor ponatinib suppress the AKT and ERK1/2 pathways leading to apoptosis.	ponatinib	71-80	AKT serine/threonine kinase 1	Homo sapiens	94-97